Literature DB >> 2056038

Aspergillus fumigatus contamination of lymphokine-activated killer cells infused into cancer patients.

P M Arnow1, S G Houchins, J M Richards, R Chudy.   

Abstract

Lymphokine-activated killer (LAK) cells, prepared by incubating autologous lymphocytes in cell culture medium with interleukin-2, selectively lyse tumor cells and are effective immunotherapy of some cancers. During a 3-month period, two patients at our center were infused with LAK cells subsequently found to have been contaminated by Aspergillus fumigatus. Each case was investigated by obtaining environmental cultures and assessing aseptic practices during LAK cell preparation. Investigation of the first case demonstrated a malfunction of the laminar air flow hood, under which interleukin-2 and the patient's lymphocytes had been added to cell culture medium, and showed heavy A. fumigatus contamination of the hood, adjacent countertop, and cell culture incubator. Despite repair of the laminar air flow hood and cleaning of the laboratory, a second case occurred, and cultures at that time implicated the humidified cell culture incubators as the source of A. fumigatus. Following incubator sterilization and removal of the humidification apparatus from the incubators, weekly environmental cultures in the LAK cell laboratory were negative, and none of the LAK cell cultures from the 20 patients treated during the ensuing 15 months grew A. fumigatus. Our findings show that growth of fungi in humidified incubators, which previously has caused contamination problems in tissue culture and clinical microbiology laboratories, can result in patient infections when humidified incubators are used to prepare cells for reinfusion.

Entities:  

Mesh:

Year:  1991        PMID: 2056038      PMCID: PMC269930          DOI: 10.1128/jcm.29.5.1038-1041.1991

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  12 in total

1.  Some observations on contamination of animal cell cultures by the fungus Aspergillus fumigatus and suggested control measures.

Authors:  J H Clarke; J A Norman; E Lavery
Journal:  Cell Biol Int Rep       Date:  1989-09

2.  Antigenemia in a rabbit model of invasive aspergillosis.

Authors:  P Phillips; G Radigan
Journal:  J Infect Dis       Date:  1989-06       Impact factor: 5.226

3.  Inadvertent intravenous infusion of Mucor during parenteral feeding of a neonate.

Authors:  N J Todd; M R Millar; S R Dealler; S Wilkins
Journal:  J Hosp Infect       Date:  1990-04       Impact factor: 3.926

4.  Fungi in fluids--a hazard of intravenous therapy.

Authors:  M H Robertson
Journal:  J Med Microbiol       Date:  1970-02       Impact factor: 2.472

5.  An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy.

Authors:  M S Klempner; R Noring; J W Mier; M B Atkins
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245

6.  A new regimen of interleukin 2 and lymphokine-activated killer cells. Efficacy without significant toxicity.

Authors:  T J Eberlein; D D Schoof; S E Jung; D Davidson; B Gramolini; K McGrath; A Massaro; R E Wilson
Journal:  Arch Intern Med       Date:  1988-12

7.  Inadvertent administration of intravenous fluids contaminated with fungus.

Authors:  J A Daisy; E A Abrutyn; R R MacGregor
Journal:  Ann Intern Med       Date:  1979-10       Impact factor: 25.391

Review 8.  NIH conference. New approaches to the immunotherapy of cancer using interleukin-2.

Authors:  S A Rosenberg; M T Lotze; J J Mulé
Journal:  Ann Intern Med       Date:  1988-06       Impact factor: 25.391

9.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

Authors:  S A Rosenberg; M T Lotze; L M Muul; A E Chang; F P Avis; S Leitman; W M Linehan; C N Robertson; R E Lee; J T Rubin
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

10.  Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.

Authors:  R I Fisher; C A Coltman; J H Doroshow; A A Rayner; M J Hawkins; J W Mier; P Wiernik; J D McMannis; G R Weiss; K A Margolin
Journal:  Ann Intern Med       Date:  1988-04       Impact factor: 25.391

View more
  1 in total

1.  Overview of a quality assurance/quality control compliance program consistent with FDA regulations and policies for somatic cell and gene therapies: a four year experience.

Authors:  G C du Moulin; Z Pitkin; Y J Shen; E Conti; J K Stewart; C Charles; D Hamilton
Journal:  Cytotechnology       Date:  1994       Impact factor: 2.058

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.